02:02 , Aug 10, 2019 |  BioCentury  |  Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

The rush to drug CD47 shows no signs of abating, with five companies launching clinical programs for cancer this year and three moving forward on the back of encouraging Phase I data. The differentiator may...
23:52 , Aug 8, 2019 |  BC Innovations  |  Tools & Techniques

Checkpoint inhibitors are bringing oncolytic viruses back into the spotlight

Early clinical readouts for next-generation oncolytic viruses are hinting at high efficacy when combined with checkpoint inhibitors, and pharmas are off to the races to find the best pairings. After more than two decades of...
17:18 , Aug 8, 2019 |  BC Innovations  |  Distillery Therapeutics

RNF2 inhibition to treat prostate cancer

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer Inhibiting the RNF2 subunit of PRC1 could treat double-negative prostate cancer (DNPC), a subtype of metastatic prostate cancer characterized by a non-responsive androgen receptor pathway and lacking neuroendocrine traits....
23:44 , Aug 6, 2019 |  BC Extra  |  Company News

Aug. 6 Company Quick Takes: Sales updates from Alnylam, Sage, Regeneron and GW; plus regulatory updates from MorphoSys and more

Alnylam's Onpattro bests consensus  Sales of amyloidosis therapy Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reached $38.2 million in 2Q19, the drug's third full quarter on the market. The figure beat analysts' consensus of $32...
22:58 , Aug 6, 2019 |  BC Extra  |  Clinical News

Leap zeroes in on subgroup for DKN-01, Keytruda combo

Shares of Leap tumbled Tuesday as investors digested updated data from the Phase I trial of DKN-01 that showed a lower response than reported in March for the mAb in combination with Keytruda for advanced...
22:35 , Aug 5, 2019 |  BC Extra  |  Clinical News

Bladder cancer data gives Tecentriq another first-line win

With more positive data in first-line bladder cancer, Roche's Tecentriq could become the leading immunotherapy agent for the indication. An interim analysis of the 1,213-patient Phase III IMvigor-130 trial showed Tecentriq atezolizumab plus chemotherapy met...
00:18 , Aug 2, 2019 |  BC Innovations  |  Distillery Therapeutics

SH2B3 as a therapeutic target for melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Inhibition of SH2B3 could help treat melanoma. Levels of SH2B3 were higher in tumor samples from 12 patients than in samples of normal skin. In a mouse melanoma cell line,...
23:10 , Aug 1, 2019 |  BC Innovations  |  Emerging Company Profile

NeoPhore: Driving neoantigen production via DNA mismatch repair

NeoPhore is turning cold tumors hot by inhibiting DNA mismatch repair to produce more of the neoantigens that trigger immune attack. Immuno-oncology companies are developing therapies based on neoantigens -- tumor-specific peptides that the immune...
04:35 , Aug 1, 2019 |  BC Innovations  |  Distillery Therapeutics

Sensitizing cancer to checkpoint inhibitors by targeting the non-coding RNA LINC01139

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Blocking the long non-coding RNA LINC01139 could sensitize checkpoint inhibitor-resistant triple-negative breast cancer (TNBC) to the therapies. High LINC01139 expression levels correlated with low tumor levels of antigen-presenting cells...
04:34 , Aug 1, 2019 |  BC Innovations  |  Distillery Therapeutics

Analogs of tumor-associated glycosphingolipids as cancer vaccines

DISEASE CATEGORY: Cancer INDICATION: Lymphoma; melanoma; lung cancer Vaccination with lipid-free analogs of tumor-associated glycosphingolipids GD2 and GD3 could treat lymphoma, melanoma and lung cancer. Mice given either the GD2- or GD3-based vaccine produced antibodies...